MedPath logoMedPath Lab

Vaccine Pre-Check

New Zealand Vaccine Pre-Check

Use this page to review preliminary vaccine suggestions for adults and selected special-risk groups in New Zealand. Results are organised by recommendation level and include funding or timing notes where relevant.

EN中文

This pre-check is designed to support early planning only. Final vaccination decisions should be confirmed against the latest edition of The Health New Zealand Immunisation Handbook, funded eligibility criteria, product availability and clinician advice.

Profile

Base demographic inputs used by the current rule engine before country-specific condition filters are applied.

Age (years)
Required
Sex
Required

Select sex first so pregnancy-related options can be filtered automatically.

Condition Flags

Additional risk and funding options unlock after sex is selected.

Select sex before using this area

Pregnancy-related options and some rule filters depend on the sex field. Choose sex first, then add only the condition flags that apply.

Ready to check

New Zealand vaccine suggestions

Enter age, sex and any relevant condition flags on the left, then submit the form to get NZ-specific recommendation tiers, funding labels and review notes.

Vaccines covered on this page

This New Zealand pre-check currently provides guidance across seven adult and special-risk vaccine topics.

Influenza

Annual vaccination; funding varies by group

COVID-19

Current higher-risk dose prioritisation; full primary-course logic not modelled in this skeleton

Tdap in pregnancy

Pregnancy-focused module

Zoster (Shingrix)

Funding and approval differ by age and immunocompromise group

Pneumococcal (PCV13 / 23PPV)

High-risk funding differs from broader clinical recommendation

HPV9 (Gardasil 9)

Funding extends to age 26 inclusive, with special-group schedules

MMR

Focus on adult susceptibility and catch-up

Reference sources

These recommendations are based on the current edition of The Health New Zealand Immunisation Handbook and related chapter-level guidance.